1399 Internet Tech (OTC:YSGG) Stock, Quote.Headers.trade-ideas

1399 Internet Technology Application Group Inc is a shell company.

399 INTERNET TECH APP GRP by 1399 INTERNET TECHNOLOGY APPLICATION GROUP INC.

1399 Internet Technology Application Group Inc

Macro Economic Events

WIIM

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher amid strength in NVIDIA and other chip stocks. Indexes are rebounding after earlier falling on August CPI data.

ALAB

AMAT

ASML

AVGO

CRDO

INDI

KLAC

LRCX

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MPWR

MRVL

ONTO

SITM

SMTK

Semiconductor shares are trading higher amid possible sympathy with NVIDIA. At the ABC 2024 Presidential Debate, Vice President Harris said she wants to invest in American-based technology to win the race on AI and quantum computing.

NVDA

NVIDIA shares are trading higher possibly following a report suggesting the U.S. Government may allow Nvidia to export its AI chips to Saudi Arabia. Additionally, At the ABC 2024 Presidential Debate, Vice President Harris said she wants to invest in American-based technology to win the race on AI and quantum computing.

<p><strong>Tetra Tech, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttek#NASDAQ">TTEK</a>) recently announced that it has secured a $39.3 million contract from the United States Agency for International Development (&quot;USAID&quot;). The latest deal will involve the company supporting USAID&#39;s Engendering Industries program.</p>
<p>As part of the single-award deal, Tetra Tech will work on enhancing gender equality and women&#39;s economic empowerment opportunities in multiple industries throughout the world. These industries include water, infrastructure, power, transportation as well as information and communications technology.</p>
<p>Under the USAID Engendering Industries program, the company&#39;s professionals will utilize data-driven change management tactics to help companies and organizations boost gender equality and economic opportunities for women globally. As part of the Engendering Industries program since 2018, TTEK has been offering technical support services to more than 68 organizations in 39 countries.</p>
<h2>Tetra Tech&#39;s Other Notable Contracts</h2>
<p>Lately, Tetra Tech has received a series of deals, which are likely to drive its growth. In July 2024, the company received a $73 million deal from the USAID to enhance the availability of cost-effective and dependable electricity across 18 nations in West Africa. Also, in March 2024, it secured a $375 million multiple-award contract from National Aeronautics and Space Administration (&quot;NASA&quot;). Per the five-year contract, Tetra Tech will offer environmental restoration and compliance services at NASA facilities across the United States.</p>
<p>In January 2024, the company secured a $34 million contract from the USAID. Per the deal, TTEK will support the USAID Integrated Land and Resource Governance II project, which is aimed at promoting sustainable economic development through better land rights governance. Also, in the same month, it secured a $24 million, single-award deal from USAID to conserve biodiversity and natural resources in Cambodia.</p>
<h2>TTEK&#39;s Zacks Rank and Price Performance</h2>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/49/77316.jpg?v=170175387" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>Tetra Tech currently carries a Zacks Rank #2 (Buy). Shares of the company gained 50.1% in the past year against the industry&lsquo;s 11% decline.</p>
<h2>Other Stocks to Consider</h2>
<p>Other top-ranked companies from the same space are discussed below.</p>
<p><strong>Flowserve Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fls#NYSE">FLS</a>) currently carries a Zacks Rank of 2.</p>
<p>FLS delivered a trailing four-quarter average earnings surprise of 18.2%. In the past 60 days, the Zacks Consensus Estimate for Flowserve&#39;s 2024 earnings has increased 3.8%.</p>
<p><strong>Crane Company</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cr#NYSE">CR</a>) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 11.2%.</p>
<p>In the past 60 days, the Zacks Consensus Estimate for CR&#39;s 2024 earnings has increased 2%.</p>
<p><strong>Parker-Hannifin Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ph#NYSE">PH</a>) currently carries a Zacks Rank of 2. PH delivered a trailing four-quarter average earnings surprise of 2.6%.</p>
<p>In the past 60 days, the consensus estimate for Parker-Hannifin&#39;s fiscal 2025 earnings has increased 1.1%.</p>
<p><a href="https://www.zacks.com/stock/news/2334556/tetra-tech-secures-39-3m-single-award-contract-from-usaid?cid=CS-BENZ-FT-analyst_blog|company_news_corporate_actions-2334556">To read this article on Zacks.com click here.</a></p>


Earnings

Large Cap

Mid Cap

News

Contracts

Markets

Analyst Ratings

Tech

Trading Ideas

TTEK

Tetra Tech Secures $39.3M Single-Award Contract From USAID

Federal Aviation Administration Head Says Safety Audit Of United Airlines "Almost Finished"

iShares MSCI Israel Capped Investable Market Index Fund

Hamas Says Its Negotiation Team Met With Qatar's PM And Egypt's Intelligence Chief In Doha On Wednesday To Discuss Latest Gaza Developments; Reiterates Readiness For 'Immediate' Ceasefire Based On U.S. Proposal Without New Conditions From Any Party

<p><strong>Render's</strong> (CRYPTO:RENDER) price has decreased 4.02% over the past 24 hours to <strong>$5.03</strong>. This is contrary to the coins performance over the past week where it has experienced an up-trend of 3.0%, moving from $4.89 to its current price.</p>
<p>The chart below compares the price movement and volatility for Render over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726081344_0.png" alt="price_chart" /></p>
<p>Render's trading volume has climbed 39.0% over the past week along with the circulating supply of the coin, which has increased 0.06%. This brings the circulating supply to 392.46 million. According to our data, the current market cap ranking for RENDER is #46 at $1.98 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726081344_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

Cryptocurrency Render Down More Than 4% Within 24 hours

Telus Forms Strategic Partnership With Mila Quebec AI Institute To Advance AI Development For The Benefit Of Society And Explore Industry Impacts For Canadian Customers

<p>Over the past 24 hours, <strong>Uniswap's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/uni/usd">UNI</a>) price has risen 3.12% to <strong>$6.94</strong>. This continues its positive trend over the past week where it has experienced a 8.0% gain, moving from $6.43 to its current price. As it stands right now, <strong>the coin's all-time high is $44.92</strong>. </p>
<p>The chart below compares the price movement and volatility for Uniswap over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726081275_0.png" alt="price_chart" /></p>
<p>The trading volume for the coin has fallen 44.0% over the past week which is opposite, directionally, with the overall circulating supply of the coin, which has increased 0.25%. This brings the circulating supply to 753.77 million, which makes up an estimated 75.38% of its max supply of 1.00 billion. According to our data, the current market cap ranking for UNI is #21 at $5.22 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726081275_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$UNI

Cryptocurrency Uniswap Rises More Than 3% In 24 hours

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Eaton Corp</strong>.</p>
<p>Looking at options history for Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) we detected 8 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $126,690 and 5, calls, for a total amount of $349,579.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $260.0 to $300.0 for Eaton Corp over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Eaton Corp options trades today is 931.33 with a total volume of 1,452.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Eaton Corp's big money trades within a strike price range of $260.0 to $300.0 over the last 30 days.</p>
<h3>Eaton Corp Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726081269_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$28.5</td>
<td>$28.1</td>
<td>$28.1</td>
<td>$290.00</td>
<td>$129.2K</td>
<td>294</td>
<td style="text-align: right;">53</td>
</tr>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$16.0</td>
<td>$15.7</td>
<td>$15.87</td>
<td>$290.00</td>
<td>$79.3K</td>
<td>461</td>
<td style="text-align: right;">197</td>
</tr>
<tr>
<td>ETN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$7.2</td>
<td>$6.7</td>
<td>$6.9</td>
<td>$290.00</td>
<td>$69.0K</td>
<td>2.1K</td>
<td style="text-align: right;">106</td>
</tr>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$3.4</td>
<td>$3.0</td>
<td>$3.4</td>
<td>$300.00</td>
<td>$64.9K</td>
<td>2.3K</td>
<td style="text-align: right;">557</td>
</tr>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$3.0</td>
<td>$2.8</td>
<td>$3.0</td>
<td>$300.00</td>
<td>$45.0K</td>
<td>2.3K</td>
<td style="text-align: right;">365</td>
</tr>
</tbody>
</table>
</p>
<h3>About Eaton Corp</h3>
<p>Founded in 1911 by Joseph Eaton, the eponymous company began by selling truck axles in New Jersey. Eaton has since become an industrial powerhouse largely through acquisitions in various end markets. Eaton's portfolio can broadly be divided into two parts: its electrical and industrial businesses. Its electrical portfolio (representing around 70% of company revenue) sells components within data centers, utilities, and commercial and residential buildings, while its industrial business (30% of revenue) sells components within commercial and passenger vehicles and aircraft. Eaton receives favorable tax treatment as a domiciliary of Ireland, but it generates over half of its revenue within the US.</p>
<p>Following our analysis of the options activities associated with Eaton Corp, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Eaton Corp</h3>
<ul>
<li>Trading volume stands at 1,383,116, with ETN's price up by 3.03%, positioned at $297.04.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 48 days.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eaton Corp options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

What the Options Market Tells Us About Eaton Corp

<p>Analysts' ratings for Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Medpace Hldgs, revealing an average target of $419.33, a high estimate of $469.00, and a low estimate of $336.00. A decline of 6.23% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726081263_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of Medpace Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$415.00</td>
<td>-</td>
</tr>
<tr>
<td>Sandy Draper</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$432.00</td>
<td>$464.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$430.00</td>
<td>$469.00</td>
</tr>
<tr>
<td>Justin Bowers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$336.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$434.00</td>
<td>$452.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$469.00</td>
<td>$456.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Medpace Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medpace Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Medpace Hldgs's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Medpace Hldgs's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MEDP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Medpace Hldgs analyst ratings.</strong></a></p>
<h2>Discovering Medpace Hldgs: A Closer Look</h2>
<p>Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.</p>
<h3>Medpace Hldgs's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Medpace Hldgs's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>14.59%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Medpace Hldgs's net margin excels beyond industry benchmarks, reaching <strong>16.73%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Medpace Hldgs's ROE excels beyond industry benchmarks, reaching <strong>12.31%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Medpace Hldgs's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>4.76%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Medpace Hldgs's debt-to-equity ratio is below the industry average. With a ratio of <b>0.17</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MEDP

Cracking The Code: Understanding Analyst Reviews For Medpace Hldgs

<p>Deep-pocketed investors have adopted a bullish approach towards Philip Morris Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PM usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Philip Morris Intl. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 46% leaning bullish and 23% bearish. Among these notable options, 2 are puts, totaling $612,600, and 11 are calls, amounting to $3,517,486.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $155.0 for Philip Morris Intl over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Philip Morris Intl's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Philip Morris Intl's whale activity within a strike price range from $70.0 to $155.0 in the last 30 days. </p>
<h3>Philip Morris Intl Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726081264_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$55.6</td>
<td>$54.9</td>
<td>$55.6</td>
<td>$70.00</td>
<td>$2.7M</td>
<td>531</td>
<td>505</td>
</tr>
<tr>
<td>PM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.1</td>
<td>$1.95</td>
<td>$1.95</td>
<td>$115.00</td>
<td>$585.0K</td>
<td>1.6K</td>
<td>3.0K</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$30.9</td>
<td>$30.3</td>
<td>$30.9</td>
<td>$95.00</td>
<td>$309.0K</td>
<td>1.3K</td>
<td>130</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$1.9</td>
<td>$1.85</td>
<td>$1.92</td>
<td>$155.00</td>
<td>$76.4K</td>
<td>1</td>
<td>442</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$13.6</td>
<td>$11.6</td>
<td>$12.5</td>
<td>$120.00</td>
<td>$75.0K</td>
<td>1.9K</td>
<td>0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Philip Morris Intl</h3>
<p>Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heatsticks, vapes, and oral nicotine offerings primarily outside of the US. With the 2022 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI has not only diversified away from smokeable products but also gained a toehold into the US to sell its iQOS heatsticks.</p>
<p>Following our analysis of the options activities associated with Philip Morris Intl, we pivot to a closer look at the company's own performance.</p>
<h3>Philip Morris Intl's Current Market Status</h3>
<ul>
<li>Trading volume stands at 2,285,746, with PM's price down by -0.09%, positioned at $126.63.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 36 days.</li>
</ul>
<h3>What The Experts Say On Philip Morris Intl</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $131.4.</p>
<ul>
<li>An analyst from B of A Securities has decided to maintain their Buy rating on Philip Morris Intl, which currently sits at a price target of $139. </li>
<li>An analyst from Barclays has decided to maintain their Overweight rating on Philip Morris Intl, which currently sits at a price target of $130. </li>
<li>An analyst from Stifel persists with their Buy rating on Philip Morris Intl, maintaining a target price of $138. </li>
<li>Maintaining their stance, an analyst from UBS continues to hold a Sell rating for Philip Morris Intl, targeting a price of $105. </li>
<li>An analyst from Barclays persists with their Overweight rating on Philip Morris Intl, maintaining a target price of $145. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Philip Morris Intl, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Looking At Philip Morris Intl's Recent Unusual Options Activity

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Paychex</strong>.</p>
<p>Looking at options history for Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) we detected 8 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% with bearish.</p>
<p>From the overall spotted trades, 6 are puts, for a total amount of $254,166 and 2, calls, for a total amount of $79,074.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $110.0 to $130.0 for Paychex over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Paychex's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Paychex's whale activity within a strike price range from $110.0 to $130.0 in the last 30 days. </p>
<h3>Paychex Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726081259_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PAYX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.45</td>
<td>$1.25</td>
<td>$1.45</td>
<td>$110.00</td>
<td>$69.7K</td>
<td>3.1K</td>
<td>19</td>
</tr>
<tr>
<td>PAYX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.5</td>
<td>$2.35</td>
<td>$2.5</td>
<td>$120.00</td>
<td>$53.0K</td>
<td>6.0K</td>
<td>1.4K</td>
</tr>
<tr>
<td>PAYX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$12.6</td>
<td>$12.2</td>
<td>$12.42</td>
<td>$120.00</td>
<td>$52.1K</td>
<td>350</td>
<td>0</td>
</tr>
<tr>
<td>PAYX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.95</td>
<td>$2.85</td>
<td>$2.85</td>
<td>$120.00</td>
<td>$39.0K</td>
<td>6.0K</td>
<td>815</td>
</tr>
<tr>
<td>PAYX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.3</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$120.00</td>
<td>$38.7K</td>
<td>6.0K</td>
<td>96</td>
</tr>
</tbody>
</table>
</p>
<h3>About Paychex</h3>
<p>Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 745,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.</p>
<p>In light of the recent options history for Paychex, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Paychex</h3>
<ul>
<li>Currently trading with a volume of 1,084,409, the PAYX's price is down by -0.92%, now at $132.88. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 14 days.</li>
</ul>
<h3>Professional Analyst Ratings for Paychex</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $128.0.</p>
<ul>
<li>An analyst from JP Morgan has decided to maintain their Underweight rating on Paychex, which currently sits at a price target of $128. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Paychex with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


PAYX

Spotlight on Paychex: Analyzing the Surge in Options Activity

<p>In the latest quarter, 10 analysts provided ratings for Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $25.1, a high estimate of $30.00, and a low estimate of $21.00. Observing a downward trend, the current average is 18.16% lower than the prior average price target of $30.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726081248_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Fortrea Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Justin Bowers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$23.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$23.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$21.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$22.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$27.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Fortrea Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Fortrea Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Fortrea Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Fortrea Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FTRE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Fortrea Holdings analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Fortrea Holdings</h2>
<p>Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.</p>
<h3>Unraveling the Financial Story of Fortrea Holdings</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Fortrea Holdings faced challenges, resulting in a decline of approximately <strong>-8.65%</strong> in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-20.89%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Fortrea Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-9.07%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Fortrea Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-3.55%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Fortrea Holdings's debt-to-equity ratio is below the industry average. With a ratio of <b>0.82</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FTRE

Analyst Expectations For Fortrea Holdings's Future

<p>EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) has outperformed the market over the past 20 years by 8.64% on an annualized basis producing an average annual return of 16.93%. Currently, EQT has a market capitalization of $19.66 billion. </p>
<p><strong>Buying $1000 In EQT:</strong> If an investor had bought $1000 of EQT stock 20 years ago, it would be worth <strong>$22,917.63</strong> today based on a price of $33.09 for EQT at the time of writing.</p>
<h3>EQT's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726081236_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $1000 Invested In EQT 20 Years Ago Would Be Worth Today

<p>Coca-Cola Consolidated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>) has outperformed the market over the past 10 years by 21.85% on an annualized basis producing an average annual return of 32.51%. Currently, Coca-Cola Consolidated has a market capitalization of $11.30 billion. </p>
<p><strong>Buying $100 In COKE:</strong> If an investor had bought $100 of COKE stock 10 years ago, it would be worth <strong>$1,682.47</strong> today based on a price of $1290.04 for COKE at the time of writing.</p>
<h3>Coca-Cola Consolidated's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726081230_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


COKE

If You Invested $100 In This Stock 10 Years Ago, You Would Have $1,700 Today

<p>Over the past 24 hours, <strong>Bitcoin Cash's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bch/usd">BCH</a>) price has risen 3.11% to <strong>$339.11</strong>. This continues its positive trend over the past week where it has experienced a 8.0% gain, moving from $314.02 to its current price. As it stands right now, <strong>the coin's all-time high is $3,785.82</strong>. </p>
<p>The chart below compares the price movement and volatility for Bitcoin Cash over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726081205_0.png" alt="price_chart" /></p>
<p>The trading volume for the coin has fallen 11.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has decreased 0.11%. This brings the circulating supply to 19.76 million, which makes up an estimated 94.09% of its max supply of 21.00 million. According to our data, the current market cap ranking for BCH is #18 at $6.70 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726081205_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$BCH

Bitcoin Cash Up More Than 3% In 24 hours

<p><strong>Kronos Worldwide, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kro#NYSE">KRO</a>) is expected to benefit from higher demand for titanium dioxide (TiO2) and easing pricing pressure this year. Cost-reduction initiatives are also expected to support margins.</p>
<p>We are positive about KRO&#39;s prospects and believe that the time is right for you to add the stock to your portfolio as it looks promising and is poised to carry the momentum ahead.</p>
<p>Let&#39;s take a look into the factors that make this Zacks Rank #2 (Buy) stock a compelling choice for investors right now.</p>
<h2>Kronos Worldwide&#39;s Stock Outperforms Industry</h2>
<p>KRO has outperformed the industry it belongs to over the past year. The company&#39;s shares have rallied 32.8% compared with a 9.6% decline of the industry.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6e/77269.jpg?v=1616124123" /></p>
<p>Image Source: Zacks Investment Research</p>
<h2>Solid Earnings Growth Prospects for KRO</h2>
<p>The Zacks Consensus Estimate for earnings for 2024 for Kronos Worldwide is currently pegged at 88 cents, reflecting an expected year-over-year growth of 304.7%. Earnings are also expected to register a 288.9% growth in third-quarter 2024.</p>
<h2>KRO&#39;s Earnings Estimates Northbound</h2>
<p>Earnings estimates for KRO have been going up over the past 60 days. The Zacks Consensus Estimate for 2024 has increased by 3.5%. The consensus estimate for the third quarter has also been revised 9.7% upward over the same time frame. The favorable estimate revisions instill investor confidence in the stock.</p>
<h2>Higher TiO2 Demand, Cost Actions Aid Kronos Worldwide</h2>
<p>Kronos is well-positioned to gain from higher demand for TiO2 in major markets. Per the company, TiO2 consumption has increased at a compound annual growth rate of around 2% since 2000. Western Europe and North America account for roughly 14% and 15% of global TiO2 consumption, respectively. These regions are expected to continue to be the biggest consumers of TiO2. Markets for TiO2 are growing in South America, Eastern Europe, the Asia Pacific region and China.</p>
<p>The company expects sales volumes in 2024 to exceed 2023 levels factoring in the recently experienced improved demand and expectations that demand will continue to improve this year.</p>
<p>Kronos Worldwide is also taking actions to reduce costs and align production and inventories to expected demand levels, which are expected to support its margins. It has increased its production rates in sync with current and expected near-term demand improvement. It expects its production rates for the balance of 2024 to be higher than the level witnessed in 2023.</p>
<p>The company&#39;s internal cost initiatives are also expected to continue to support margins in 2024. Reduced energy costs along with its cost-cutting initiatives and the realization of selling price increases are likely to result in improved margins on a year-over-year basis this year. The company has undertaken TiO2 selling price hikes, which need to be sustained to attain margins in line with historical levels. KRO expects to report higher operating results on a year-over-year basis for full-year 2024 based on the expected improved demand, higher selling prices and reduced production costs.</p>
<div class="chart_embed">
<h3>Kronos Worldwide Inc Price and Consensus</h3>
<p><img alt="Kronos Worldwide Inc Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/76/1726047534.png" style="height:265px; width:580px" title="" /></p>
<p><span style="font-size:13px">Kronos Worldwide Inc price-consensus-chart</span><span style="font-size:13px"> | </span><span style="font-size:13px">Kronos Worldwide Inc Quote</span></p>
</div>
<h2>Stocks to Consider</h2>
<p>Other top-ranked stocks in the Basic Materials space are, <strong>Hawkins, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hwkn#NASDAQ">HWKN</a>), <strong>IAMGOLD Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iag#NYSE">IAG</a>) and <strong>Eldorado Gold Corporation </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ego#NYSE">EGO</a>), each sporting a Zacks Rank #1 (Strong Buy).</p>
<p>The Zacks Consensus Estimate for Hawkins&#39; current fiscal-year earnings is pegged at $4.14, indicating a rise of 15.3% from year-ago levels. The Zacks Consensus Estimate for HWKN&#39;s current fiscal-year earnings has increased 12.8% in the past 60 days. The stock has rallied around 103% in the past year.</p>
<p>The consensus estimate for IAMGOLD&#39;s current-year earnings has increased by 46.4% in the past 60 days. IAG beat the consensus estimate in each of the last four quarters with the average surprise being 200%. Its shares have shot up 111% in the past year.</p>
<p>The Zacks Consensus Estimate for Eldorado Gold&#39;s current year earnings is pegged at $1.35 per share, indicating a year-over-year rise of 136.8%. EGO beat the consensus estimate in each of the last four quarters, with the average earnings surprise being 430.3%. The company&#39;s shares have rallied roughly 69% in the past year.</p>
<p><a href="https://www.zacks.com/stock/news/2334557/here-s-why-you-should-buy-kronos-worldwide-stock-right-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2334557">To read this article on Zacks.com click here.</a></p>


Earnings Beats

Penny Stocks

Small Cap

HWKN

Here's Why You Should Buy Kronos Worldwide Stock Right Now

<p><strong>UnitedHealth Group Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reportedly announced on Tuesday that it will remove <strong>AbbVie Inc.&#8217;s</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) blockbuster drug Humira from some of its preferred reimbursement lists starting January 1, 2025. The company will recommend lower-cost biosimilar versions instead.</p>
<p>This move is part of a larger trend in the U.S. pharmaceutical market, as health plans seek to cut costs by promoting alternatives to high-priced drugs.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">FTC Investigation Uncovers Anti-Competitive Practices By Handful Of Pharmacy Benefit Managers, Including CVS Health, UnitedHealth</a>.</strong></p>
<p>Reuters highlights that <strong>Amgen Inc&#8217;s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Amjevita, managed by its pharmacy benefits unit, Optum Rx, is among the biosimilars covered under UnitedHealth&#8217;s lists for commercial health plans.</p>
<p>With this decision, Optum becomes the last of the three largest U.S. pharmacy benefit managers (PBMs) to exclude Humira.</p>
<p><strong>Cigna Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) announced last month that it would remove Humira from some of its lists in 2025, following a similar decision by <strong>CVS Health Inc&#8217;s</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark unit in April.</p>
<p>CVS&#8217;s action led to a swift shift, with more patients transitioning to <strong>Sandoz Group AG&#8217;s</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZNY#OTC">SDZNY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZXF#OTC">SDZXF</a>) biosimilar version of Humira in just three weeks than in the previous 15 months combined.</p>
<p>Cigna plans to cover biosimilars like Boehringer Ingelheim&#8217;s Cyltezo, Simlandi from <strong>Teva Pharmaceutical Industries Ltd</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), and <strong>Alvotech&#8217;s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) products, including an unbranded version of Sandoz&#8217;s Hyrimoz, as replacements for Humira.</p>
<p>UnitedHealth noted that patients would still have access to Humira until the FDA designates the preferred biosimilars as interchangeable with the original drug, per the report. The FDA is expected to make this designation in 2025.</p>
<p>Despite the growing competition, AbbVie has managed to retain a dominant share of the U.S. Humira market throughout 2023. This has been achieved through favorable negotiations with PBMs, even as biosimilar alternatives from companies like <strong>Pfizer Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) entered the market.</p>
<p>As per a Reuters report, Humira has still managed to retain over 80% of its patients even after facing lower-priced rivals in the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/04/38468317/arthritis-patients-cignas-evernorth-to-offer-humira-biosimilar-at-no-out-of-pocket-cost" rel="noreferrer noopener">U.S. over the past year</a>.</p>
<p>Following their launch last year, pharmacy benefit managers largely influenced patient access, with minimal incentive for doctors to switch to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39228916/abbvies-arthritis-drug-humira-retains-market-dominance-despite-biosimilar-competition-challenges-" rel="noreferrer noopener">these alternatives</a>.</p>
<p>In May, Cantor Fitzgerald said AbbVie had positioned itself to absorb Humira biosimilar erosion and achieve modest <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38899905/abbvie-is-successfully-positioned-to-absorb-humira-biosimilar-erosion-analyst" rel="noreferrer noopener">operational revenue growth</a>.</p>
<p><strong>Price Action:</strong> UNH stock is down 2% at $587.07 at last check Wednesday.</p>
<p><em>Photo via Shutterstock</em></p>
<p><strong>Disclaimer:</strong> This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/biotech/24/09/40817991/gsk-halts-herpes-simplex-virus-vaccine-development-clears-path-for-other-contenders-like-moderna-" target="_blank" rel="noreferrer noopener">GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech</a>.</strong></li>
</ul>


Biotech

Equities

Health Care

Media

General

ABBV

ALVO

AMGN

SDZNY

SDZXF

TEVA

UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars

<p>Former President <a href="https://www.benzinga.com/topic/donald-trump"><strong>Donald Trump</strong></a>'s responses in Tuesday&#8217;s <a href="https://www.benzinga.com/news/24/09/40811055/polling-veteran-nate-silver-says-kamala-harris-got-the-debate-she-wanted-as-fatigued-trump-couldnt-b">presidential debate</a> did not always correspond to the questions asked by the two ABC reporters. Instead, the GOP candidate seemed to be stuck in a loop of drugs, murders and the illegal immigrants who — in his mind — are to blame for both.  </p>
<p>"They have, and she has, destroyed our country with policy that's insane. Almost policy that you'd say, ‘They have to hate our country,'" Trump said, referring to the record-high migrant crossings into the U.S. from Mexico under the Biden administration. Although there's been a sharp drop in migration at the <a href="https://www.benzinga.com/topic/us-mexico-border">US-Mexico border</a> since President <strong>Joe Biden</strong>'s June mandate <a href="https://www.benzinga.com/government/24/06/39144853/biden-to-sign-executive-order-to-limit-asylum-seekers-crossing-us-mexico-border-report">limiting border crossings </a>went into effect.</p>
<h2 class="wp-block-heading"><strong>They're Invading Our Towns, Eating Our Pets, Smuggling Drugs</strong></h2>
<p>"You look at Springfield, Ohio, you look at Aurora in Colorado. They are taking over our towns, they are taking over buildings, they're going in violently," Trump said. "These are the people that she and Biden let into our country, and they're destroying our country."</p>
<p>Trump went on to reference unsubstantiated claims that Haitian immigrants in Springfield, Ohio, have been eating residents&#8217; pets: &#8220;In Springfield, they&#8217;re eating the dogs. The people that came in. They&#8217;re eating the cats.&#8221;</p>
<p>ABC's <strong>David Muir</strong> fact-checked the pet-eating story and found no evidence that Haitian immigrants in Springfield are dining on people's pets. But that didn't deter Trump from his favorite topic. He once again blamed the Biden-Harris administration for the influx of immigrants, adding that a Harris administration would open the doors to even more.</p>
<p>"This will be one of the greatest mistakes in history for them to allow," Trump said. "And I think they did it because they think it's going to get them votes, but it's not worth it."</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40817347/donald-trump-lost-debate-to-kamala-harris-will-lose-ground-in-the-polls-polymarket-traders">Donald Trump Lost Debate To Kamala Harris, Will Lose Ground In The Polls, Polymarket Traders Say: Will There Be A Rematch?</a></strong></p>
<h2 class="wp-block-heading"><strong>JD Vance Weighs In</strong></h2>
<p>In comments <a href="https://www.google.com/search?q=ABC+news+talks+to+jd+vance+after+debate&amp;rlz=1C5CHFA_enUS1056US1057&amp;oq=ABC+news+talks+to+jd+vance+after+debate&amp;gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIHCAEQIRigATIHCAIQIRigATIHCAMQIRigATIHCAQQIRigATIHCAUQIRigAdIBCTE5MDU3ajBqN6gCALACAA&amp;sourceid=chrome&amp;ie=UTF-8#fpstate=ive&amp;vld=cid:db66881d,vid:nYnIrWddayA,st:0">made to ABC News</a> following the debate, Ohio Senator and Trump's running mate <strong><a href="https://www.benzinga.com/markets/cannabis/24/09/40764643/jd-vance-accuses-kamala-harris-of-allowing-cartels-to-sex-traffic-minors-citing-thousands-of-mis">JD Vance </a></strong>got more specific about the topic.</p>
<p>In response to a question about the economy, Vance jumped swiftly to the Southern border, "They [the American people] can't afford housing and a lot of their kids are dying of fentanyl overdoses because Kamala Harris has let the Mexican drug cartels take over the Southern border," Vance said.</p>
<p><strong>Fact Check:</strong> The vast majority of <a href="https://www.benzinga.com/topic/fentanyl">fentanyl</a> comes through legal ports of entry, according to <a href="https://www.cbp.gov/newsroom/stats/drug-seizure-statistics" target="_blank" rel="noreferrer noopener">data from U.S. Customs and Border Protection</a> and the people bringing it into the U.S. are native-born Americans. The data also shows that 80% of those prosecuted and convicted of federal drug trafficking offenses have been U.S. citizens, according to <strong>Tara McGrath,</strong> U.S. Attorney for the Southern District of California.</p>
<p>"They are people who have the ability to cross but also are going to be able to slip under the radar," McGrath <a href="https://www.kpbs.org/news/border-immigration/2024/08/29/american-citizens-smuggle-more-fentanyl-into-the-u-s-than-migrants-data-show">said</a> in a recent KPBS report.</p>
<p>McGrath dismissed the idea that migrants and asylum seekers are the ones primarily bringing fentanyl into the country. "That narrative is a dangerous misconception because that is not who we are seeing," she said.</p>
<p><strong>Now Read:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40811055/polling-veteran-nate-silver-says-kamala-harris-got-the-debate-she-wanted-as-fatigued-trump-couldnt-b"><strong>Polling Veteran Nate Silver Says Kamala Harris Got The Debate She Wanted As Fatigued Trump Couldn&#8217;t Bring His &#8216;A-Game&#8217; After The Initial Momentum</strong></a></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

1399 Internet Tech

1399 Internet Tech (YSGG) Forecast

1399 Internet Tech (OTC:YSGG) Stock, Quote.Headers.trade-ideas